Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Treprostinil Palmitil Inhalation Powder in PH-ILD
NCT05649722Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of treprostinil palmitil in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Insmed Incorporated. Started May 2023; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT05649722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649722.